22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
16:52 , Oct 19, 2018 |  BC Extra  |  Preclinical News

Study uncovers large batch effects in TCGA exome sequencing data

A preprint article published in bioRxiv identified large cross-institutional batch effects for a subset of The Cancer Genome Atlas data. The report provides a warning to all multisite sequencing consortia, and calls for re-examining results...
16:19 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest CAR T cells targeting ALCAM and HER2 could help treat brain cancer. The cells are generated by conjugating T cells expressing HER2-targeting CARs to a construct consisting of pentamers...
17:37 , Sep 21, 2018 |  BC Week In Review  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...
13:46 , Sep 20, 2018 |  BC Extra  |  Financial News

DePinho's STAT3 company Tvardi raises $9M series A

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription...
22:56 , Sep 5, 2018 |  BC Extra  |  Preclinical News

Two papers open door to T cell brain entry for glioblastoma therapy

Two new studies have proposed solutions to different barriers that prevent T cells from entering the brain to attack glioblastoma. Glioblastoma patients often have low T cell counts, and their tumors’ ability to evade immune...
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
19:59 , Jun 15, 2018 |  BC Week In Review  |  Financial News

After announced merger, TapImmune raises $70M

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 June 8 after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors...
19:14 , Jun 8, 2018 |  BC Extra  |  Financial News

TapImmune shares climb on $70M offering

TapImmune (NASDAQ:TPIV) jumped $3.05 (51%) to $9 Friday after it priced a $70 million private placement led by new investor New Enterprise Associates. The company is selling 17.5 million shares at $4. New investors Aisling...
18:53 , Jun 1, 2018 |  BC Week In Review  |  Company News

TapImmune, Marker Therapeutics merge

TapImmune (NASDAQ:TPIV) will merge with Marker Therapeutics Inc. (New Brighton, Minn.) to create a new cell therapy company. The merged company will use Marker Therapeutics's multi-antigen targeted cell therapy platform with TapImmune's peptide vaccine portfolio....